Federal contract award
75A50122F61001
INHALED ANTI-MUSCARINIC AGENTS AS CONTINGENCY MCMS AGAINST NERVE AGENT-INDUCED BRONCHORRHEA
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | 75A50122D00007 |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $3.6M |
| Current contract value | $3.6M |
| Potential contract value / ceiling | $3.6M |
| Start date | Sep 23, 2022 |
| Current end date | Sep 30, 2024 |
| Potential end date | Sep 30, 2024 |
| Latest award activity | Jan 20, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 2 of 2 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jan 20, 2026 | P00010 | $0 | INHALED ANTI-MUSCARINIC AGENTS AS CONTINGENCY MCMS AGAINST NERVE AGENT-INDUCED BRONCHORRHEA SUPPLEMENTAL FUNDING DUE TO HIGHER THAN EXPECTED MODEL DEVELOPMENT COSTS, NECESSARY TO COMPLETE THE REMAINING MCM EFFICACY STUDY TASK. PREVIOUS OBLIGATE |
| Nov 24, 2025 | P00009 | $0 | INHALED ANTI-MUSCARINIC AGENTS AS CONTINGENCY MCMS AGAINST NERVE AGENT-INDUCED BRONCHORRHEA SUPPLEMENTAL FUNDING DUE TO HIGHER THAN EXPECTED MODEL DEVELOPMENT COSTS, NECESSARY TO COMPLETE THE REMAINING MCM EFFICACY STUDY TASK. PREVIOUS OBLIGATE |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.